Mechanisms of MPP+ Neurotoxicity: Oxyradical and Mitochondrial Inhibition Hypotheses

  • Juan R. Sanchez-Ramos
  • Franz Hefti
  • Gary E. Hollinden
  • Thomas J. Sick
  • Myron Rosenthal

Abstract

Recent studies demonstrate that 1-methyl-4-phenylpyridinium (MPP+) is selectively toxic to dopaminergic (DA) neurons. Investigations suggest that this selectivity results primarily from the affinity of MPP+ for the dopamine reuptake system which results in preferential accumulation of the toxin within the terminals of the nigrostriatal dopaminergic (DA) system (Javitch and Snyder, 1985;Pileblad and Carlssen, 1985; Mayer et al. 1986).

Keywords

Toxicity Dopamine Glutathione Pyridine Neurol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bannon MJ, Goedert M, Williams B. The possible relation of glutathione, melanin and MPTP to Parkinson’s disease. Biochem. Pharmacol. 33: 2697–2698, 1984PubMedCrossRefGoogle Scholar
  2. DiMonte, D, Sandy MS, Ekstrom G and Smith MT. Comparative studies on the mechanisms of paraquat and MPP + cytotoxicity. Biochem. Biophys. Res. Com. 137: 303–309, 1986CrossRefGoogle Scholar
  3. Hollinden GE, Sanchez-Ramos JR, Sick TJ, and Rosenthal M. MPP+ increases extracellular potassium in rat striatal slices: preliminary evidence that consequences of MPP+ neurotoxicity are spread beyond dopaminergic terminals. Neurosci. Abst. 113; 1502, 1987Google Scholar
  4. Javitch J A and Snyder SH: Uptake of MPP+ by dopaminergic neurons explains selectivity of parkinsonism inducing neurotoxin MPTP. Europ. J. Pharmacol. 106: 455–56, 1984Google Scholar
  5. Jellinger K. The pathology of Parkinsonism. In: Movement Disorders. Marsden CD, Fahn S. (eds) Butterworth, Boston 124–150, 1987Google Scholar
  6. Kaufman LM and Barrett JN. Serum factor supporting long term survival of rat central neurons in culture. Science 220:13941396, 1983PubMedCrossRefGoogle Scholar
  7. Kopin IJ. Toxins and Parkinson’s Disease: MPTP Parkinsonism in Humans and Animals. In Advances in Neurology Vol 45: Raven Press, NY. 137–144, 1986.Google Scholar
  8. LaManna LC, Pikarsky SM, Sick TJ, Rosenthal M. A rapid scanning spectrophotometer designed for biological tissues in vitro or in vivo. Anal. Biochem. 144:483–493,1985PubMedCrossRefGoogle Scholar
  9. Mayer RA, Kindt MV, Heikkila RE, Prevention of the nigiostriatal toxicity of MPTP by inhibitors of 3,4 dihyd-roxyphenylethylamine transport. J of Neurochem. 47:1073–1079, 1986CrossRefGoogle Scholar
  10. Mayes PA. Biological Oxidation. In, Review of Physiological Chemistry. Eds., Harper HA, Rodwell VW, Mayes PA. Lange, Chicago, 266–284, 1979Google Scholar
  11. Nicklas WJ, Vyas I and Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by MPP+, a metabolite of the neurotoxin MPTP. Life Sci. 36:2503–2508, 1985PubMedCrossRefGoogle Scholar
  12. Perry TL, Yong VW, Jones K, Wright JM. Manipulation of glutathione contents fails to alter dopaminergic nigiostriatal neurotoxicity of MPTP in the mouse. Neurosci. Lett. 70: 261–265, 1986PubMedCrossRefGoogle Scholar
  13. Pikarsky SM, LaManna JC, Sick TJ, Rosenthal M. A computer assisted rapid-scanning spectrophotometer with applications to tissues in vitro and in vivo. Comp. Biomed. Res. 18: 408–421, 1985CrossRefGoogle Scholar
  14. Pileblad E, and Carlsson A: catecholam¡ne-uptake inhibitors prevent the neurotoxicity of MPTP in the mouse brain. Neuropharmacol 24: 689–92, 1985CrossRefGoogle Scholar
  15. Ramsay RR, Salach JI, Singer TP. Uptake of the neurotoxin MPP+ by mitochondria and its relation to the inhibition of the mitochondrial oxidatin of NAD +-linkedjsubstrates by MPP+. Biochem. Biophys. Res. Com. 134:743–748, 1986aPubMedCrossRefGoogle Scholar
  16. Ramsay RR, Salach JI, Dadgar J, Singer TP. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem. Biophys. Res. Com. 135:269–275,1986PubMedCrossRefGoogle Scholar
  17. Sanchez-Ramos JR, Barrett, JN, Goldstein M, Weiner WJ, and Hefti F. MPP+, but not MPTP selectively destroys dopaminergic neurons in cultures of dissociated rat mesencephalic neurons. Neurosci. Lett. 72: 215*#x2013;220,1986.CrossRefGoogle Scholar
  18. Sanchez-Ramos JR, Michel P, Weiner WJ, and Hefti F. Selective destruction of cultured dopaminergic neurons from embryonic rat mesencehalon: cytochemical and morphological evidence. J. Neurochem. (in press, 1988a)Google Scholar
  19. Sanchez-Ramos JR, Hollinden GE, Sick TJ, Rosenthal M. 1-methyl-4phenylpyridinium (MPP+) increases oxidation of cytochrome b in rat striatal slices. Brain Research 443:183–189, 1988bPubMedCrossRefGoogle Scholar
  20. Sershen H, Reith ME A, Hashim A and Lajtha A. Protection against MPTP neurotoxicity by the antioxidant ascorbic acid. Neuropharmacol. 24: 1257–1259, 1985CrossRefGoogle Scholar
  21. Sick TJ, Rosenthal M, LaManna JC, Lutz PL. Brain potassium ion homeostasis during anoxia and metabolic inhibition in the turtle and rat. Amer. J. Physiol. 243: R281–R288, 1982.PubMedGoogle Scholar
  22. Singer TP, Castagnoli N, Ramsay RR and Trevor AJ. Biochemical events in the development of parkinsonism induced by MPTP. J. Neurochem 49: 1–8, 1987PubMedCrossRefGoogle Scholar
  23. Turrens JF, Alexandre A, Lehninger AL. Ubisemiquinone is the electron donor for superoxide formation by Complex III of heart mitochondria. Arch. Biochem. Biophys. 237:408–414,1985PubMedCrossRefGoogle Scholar
  24. Vyas I, Heikkila RE and Nicklas WJ. Studies on the neurotoxicity of MPTP: Inhibition of NAD-linked substrate oxidation by its metabolite MPP+. J. Neurochem. 46: 1501–1507, 1986PubMedCrossRefGoogle Scholar
  25. Wagner Gc, Carelli RM and Jarvis MF. Ascorbic acid reduces the dopamine depletion induced by methamphetamine and MPP+. Neuropharmacol. 25: 559–61, 1986CrossRefGoogle Scholar
  26. Yong VW, Perry TL and Krisman AV. Depletion of Glutathione in brainstem of mice caused by MPTP is prevented by anti-oxidant pretreatment. Neurosci. Lett. 63: 56–60, 1986PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Juan R. Sanchez-Ramos
    • 1
  • Franz Hefti
    • 1
  • Gary E. Hollinden
    • 1
  • Thomas J. Sick
    • 1
  • Myron Rosenthal
    • 1
  1. 1.Dept. of NeurologyUniversity of Miami School of MedicineMiamiUSA

Personalised recommendations